Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214201 · ClinicalTrials.gov registry record · NA
Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation
A NA study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00214201 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 40 participants.
The verdict
NCT00214201, a NA study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of maintenance calcineurin inhibitor (CI) therapy.
Interventions
- DRUG Calcineurin inhibitor withdrawal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-05 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214201
The ClinicalTrials.gov registry entry for NCT00214201 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Calcineurin inhibitor withdrawal is the first listed.
NCT00214201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214201 about?
NCT00214201 is a clinical study titled "Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation". The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of maintenance calcineurin inhibitor (CI) therapy.
What is the current status of trial NCT00214201?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2003-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00214201?
The interventions under investigation include: Calcineurin inhibitor withdrawal (DRUG).
Who is sponsoring clinical trial NCT00214201?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.